Oncology Brothers: Practice-Changing Cancer Discussions

Breast Cancer ASCO 2024 Practice Changing Highlights - Discussion with Dr. Erika Hamilton

Join the Oncology Brothers podcast as they dive into the highlights from ASCO 2024 with special guest Dr. Erika Hamilton, a breast medical oncologist from the Sarah Cannon Research Institute. In this episode, they discuss key abstracts in the world of breast cancer, including updates on RxPonder, PostMonarch, INAVO120, DESTINY-Breast06, and the Emerald Trial. Dr. Hamilton provides valuable insights on biomarker testing, CDK4/6 inhibitors, and groundbreaking advancements in HER2-targeted therapies. Discover how these studies are shaping treatment strategies for hormone receptor positive, HER2-low, and HER2-positive breast cancer patients. Don't miss out on this informative discussion packed with practical insights for community oncologists. Stay tuned for more ASCO 2024 highlights from the Oncology Brothers podcast.
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com

Lung Cancer ASCO 2024 Practice Changing Highlights - Discussion with Dr. Joshua Sabari

In this episode, hosts Drs. Rahul and Rohit Gosain are joined by special guest Dr. Joshua Sabari, a thoracic medical oncologist from NYU Langone Health. Together, they dive into the highlights from ASCO 2024, focusing on key studies in lung cancer.Here's a quick summary of what you can expect in this episode:•⁠  ⁠LAURA Trial: Discussing the use of Osimertinib as a consolidation approach after chemoradiation in unresectable stage 3 non-small cell lung cancer patients with common EGFR mutation.•⁠  ⁠MARIPOSA Study: Exploring the potential of Amivantamab and Lazertinib in common EGFR mutations.•⁠  ⁠CROWN Study and other ALK inhibitors: Alectinib, Lorlatinib, and Brigatinib for metastatic non-small cell lung cancer.•⁠  ⁠ADRIATIC Study: Examining the use of Durvalumab after concurrent chemoradiation in limited-stage small cell lung cancer.
•⁠ PALOMA-3 Trial: Discussing subcutaneous Amivantamab vs. IV Amivantamab with Lazertinib
Join the Oncology Brothers and Dr. Sabari as they break down these practice-changing studies and provide insights into the latest advancements in lung cancer treatment. Don't miss out on this informative and engaging discussion!
Stay tuned for more ASCO 2024 highlights and updates on GI, GU, and breast cancer in the upcoming episodes. Subscribe to the Oncology Brothers Podcast for the latest in oncology news and research. Thank you for listening!
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com

Multidisciplinary Treatment Approach for Rectal Cancer - Discussion with Drs. Deb Schrag & Krishan Jethwa

Welcome to another insightful episode of the Oncology Brothers podcast! In this episode, hosts Rahul and Rohit Gosain delve into the world of locally advanced rectal cancer, focusing on the latest treatment strategies and advancements in the field.
Joined by esteemed guests Dr. Deborah Schrag, a medical oncologist from Memorial Sloan Kettering Cancer Center, and Dr. Krishan Jethwa, a radiation oncologist from the Mayo Clinic, the discussion centers around the groundbreaking Prospect study. This study challenges the traditional approach to rectal cancer treatment, emphasizing the importance of balancing therapeutic efficacy with minimizing chronic side effects.
The conversation covers a range of topics, from the utilization of different chemotherapy regimens to the evolving paradigm of radiation therapy. Dr. Schrag and Dr. Jethwa provide valuable insights into determining the optimal treatment course for patients with locally advanced rectal cancer, including the selective omission of surgery and the significance of MSI high status in treatment decisions.
Tune in to learn about the latest advancements in rectal cancer treatment, the implications of the Prospect study, and the importance of personalized, multidisciplinary approaches in oncology care. Don't miss out on this informative discussion that sheds light on the complexities of managing rectal cancer and the evolving treatment landscape.
Stay informed and up-to-date with the Oncology Brothers podcast as they continue to explore the dynamic world of oncology treatment. Subscribe now and join the conversation!
Guests:
Dr. Deborah Schrag, Medical Oncologist, Memorial Sloan Kettering Cancer Center
Dr. Krishan Jethwa, Radiation Oncologist, Mayo Clinic

Zanubrutinib - FDA Approval, Efficacy & Safety Profile in CLL - Discussion with Dr. Shadman

Join Rahul and Rohit Gosain, the Oncology Brothers, in this insightful podcast episode where they discuss the latest advancements in hematology and oncology. In this episode, they are joined by Dr. Mazyar Shadman from Fred Hutch Cancer Center to delve into the Sequoia and Alpine trials that led to the approval of Zanubrutinib in CLL.
Key Points Discussed:
• The Sequoia trial focused on Zanubrutinib in first-line CLL treatment, showcasing its superiority over traditional chemotherapy.
• The Alpine study compared Zanubrutinib to Ibrutinib in relapsed/refractory settings, demonstrating Zanubrutinib's efficacy and safety profile.
• Acalabrutinib and Zanubrutinib were indirectly compared in a post-analysis, shedding light on their differences.
• Dr. Shadman provides insights on managing common side effects of Zanubrutinib, highlighting its improved tolerability.
Tune in to this episode for a comprehensive discussion on Zanubrutinib in CLL, including trial outcomes, comparisons, and practical considerations for patient care. Stay informed with the Oncology Brothers as they navigate the evolving landscape of oncology treatments

How to treat Myelofibrosis - Discussion with Dr. Naveen Pemmaraju

Join the Oncology Brothers, Rahul and Rohit Gosain, in this informative podcast episode as they discuss the complexities of myelofibrosis, a challenging blood cancer. They are joined by expert Dr. Naveen Pemmaraju from MD Anderson Cancer Center, who provides valuable insights into diagnosing and managing myelofibrosis.
In this episode, they discuss the importance of a thorough diagnostic workup, including bone marrow biopsy, laboratory values, and clinical history. Dr. Pemmaraju highlights the significance of risk stratification using various scoring systems and the role of molecular analysis in determining prognosis.The conversation also covers the current treatment landscape for myelofibrosis, focusing on JAK inhibitors such as ruxolitinib, fadratinib, pacritinib, and momelotinib. The hosts and guest expert explore the unique side effects of these medications and strategies for managing them effectively.
Listeners will gain valuable insights into supportive care options for anemia, thrombocytopenia, and leukopenia, including the use of erythropoietin-stimulating agents and other therapeutic interventions. The episode emphasizes the importance of considering allogeneic stem cell transplant as a potential curative option for high-risk patients.
Don't miss this comprehensive discussion on myelofibrosis, packed with practical information and expert advice. Tune in to the Oncology Brothers podcast to stay informed about the latest developments in hematology and oncology.

Understanding Disparities in Colorectal Cancer Care

In this podcast episode from the Oncology Brothers delve into the needs of different patient populations in colorectal cancer. Joined by Dr. Tanios Bekaii-Saab, a medical oncologist, and Ms. Deneen Richmond, a patient advocate, nurse, and the President of the Doctors Community Medical Center, the discussion highlights disparities in access to colorectal cancer screening and treatments among various communities. Deneen shares her personal journey as a patient, emphasizing the importance of trust and being heard in healthcare. The episode also explores strategies to raise awareness and educate different patient groups, including leveraging trusted voices and community outreach. Tune in for valuable insights on understanding and addressing the diverse needs of patients in colorectal cancer care.

Relapsed/Refractory Multiple Myeloma Treatment Algorithm with Dr. Samer Al’Hadidi

In this episode of our hematology podcast, we delve into the world of relapsed and refractory multiple myeloma with Dr. Samir A. Al-Hadidi from the University of Arkansas.
Join us as we discuss the evolving treatment options for patients who experience relapse or disease progression after initial therapy. Dr. Al-Hadidi provides valuable insights into monitoring patients, discussing escalating treatments, and the role of novel therapies such as CAR-T and bispecific antibodies.
From monitoring strategies to managing side effects, this episode of oncology podcast covers essential information for community oncologists caring for patients with relapsed or refractory multiple myeloma.
Don't miss out on this informative discussion on the current treatment landscape for multiple myeloma. Stay informed and stay connected with the latest advancements in hematology.

Liver Directed Therapies - Interventional Radiology & Radiation Oncologist Perspective

In this episode of the Oncology Brothers podcast, join Drs. Rahul and Rohit Gosain as they delve into the world of localized treatment options for gastrointestinal malignancies. They are joined by experts in the field, Drs. Nina Sanford, Jeffrey Ryckman, and Harris Chengazi, who provide insights into radiation oncology and interventional radiology modalities for treating liver cancer.
The discussion covers the basics of radiation oncology terminology, including SRS, SBRT, and proton therapy, and how these modalities have evolved over the last decade. The experts also discuss the various tools available in the interventional radiology toolkit, such as ablation techniques, chemoembolization, and radioembolization.
Listeners gain valuable insights into the considerations for referring patients with liver-confined hepatocellular carcinoma to radiation oncologists or interventional radiologists, depending on the size of the tumor and underlying liver function. The experts emphasize the importance of a multidisciplinary approach in cancer care to ensure the best treatment outcomes for patients.
Tune in to learn about the side effects of SBRT, the nuances of combining different treatment modalities, and the significance of collaboration among oncology specialists. This episode highlights the importance of understanding and appreciating the diverse treatment options available for cancer patients.
Don't miss out on this informative discussion on localized treatment options for gastrointestinal malignancies with the Oncology Brothers podcast.
 
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com

Discussing Treatment Algorithm for Newly Diagnosed Multiple Myeloma with Dr. Caitlin Costello

Welcome back to another informative episode of the Oncology Brothers podcast! In this episode, hosts Rahul and Rohit Gosain are joined by Dr. Caitlin Costello, an associate professor specializing in multiple myeloma at UC San Diego. Together, they delve into the evolving landscape of newly diagnosed multiple myeloma, covering essential topics such as diagnostic workup, treatment paradigms, and the role of minimal residual disease (MRD) in monitoring response.
Dr. Costello provides valuable insights into the minimal workup required before initiating treatment for multiple myeloma, emphasizing the importance of advanced imaging techniques and specific biomarkers for risk assessment. The discussion also touches on tailored treatment approaches for transplant-eligible and transplant-ineligible patients, as well as maintenance therapy considerations based on risk profiles.
Throughout the episode, key points such as the use of quadruplet therapy, the significance of MRD negativity, and strategies for managing high-risk patients are explored in detail. Dr. Costello also shares practical tips for community oncologists managing multiple myeloma patients, including the importance of biomarker monitoring and prophylactic measures.
Don't miss this insightful conversation that sheds light on the latest advancements in multiple myeloma care. Stay informed and up-to-date with the Oncology Brothers podcast as they continue to provide valuable insights for oncology professionals. Subscribe now to stay connected with the latest developments in hematology oncology!
 
Website: http://www.oncbrothers.com/
Twitter: https://twitter.com/oncbrothers
Contact us at info@oncbrothers.com

Discussion on Evolving CLL Treatment Strategies with Dr. Nitin Jain

In this informative podcast episode, the Oncology Brothers delve into the world of hematologic malignancies, focusing specifically on Chronic Lymphocytic Leukemia (CLL). Dr. Nitin Jain from MD Anderson Cancer Center joins the discussion, sharing insights on the latest treatment options and guidelines for CLL.
The episode covers essential topics such as determining when a patient with CLL needs treatment, the minimal workup required for scans and biopsies, and the decision-making process between time-limited venetoclax and long-term BTK inhibitors. Dr. Jain also discusses the use of second-generation BTK inhibitors like Acalabrutinib and Zanabrutinib, as well as the recent approvals of Partibrutinib and CAR-T  for third-line treatment.
Tune in to gain a deeper understanding of CLL treatment strategies, managing side effects, and the evolving landscape of hematologic malignancies. Don't miss out on this insightful conversation that will benefit both healthcare professionals and patients navigating CLL treatment options.
Stay informed and stay tuned for upcoming episodes on multiple myeloma and myelofibrosis with the Oncology Brothers. Subscribe now to stay updated on the latest in oncology care.